



CONTENTS

CHAPTERS NO.	TITLE	PAGE NO.
CHAPTER 1	INTRODUCTION	1
1.1	Hyperlipidemia	1
1.2	Treatment of hypelipidemia	4
1.3	References	8
CHAPTER 2	DRUGS SELECTED FOR THE STUDY	10
2.1	Single components	10
2.2	Combination components	19
2.3	References	21
CHAPTER 3	REVIEW OF LITERATURE	23
CHAPTER 4	AIMS & OBJECTIVES	51
CHAPTER 5	APPROACH TO THE DEVELOPMENT OF ANALYTICAL METHODS	55
5.1	Spectrophotometric methods	55
5.2	Chromatographic methods	60
5.3	Validation terminology	60
5.3.1	Spectrophotometric methods	
5.3.2	Chemometric methods	
5.3.3	Chromatographic methods	
5.4	Bioanalytical methods	66
5.5	Stress degradtation studies	72
5.6	Statistical methods used to study and compare analytical methods	75
5.7	References	77
CHAPTER 6	PRELIMINARY WORK	81

CHAPTER	EXPERIMENTAL WORK	90
7		
7.1	SINGLE COMPONENT	
7.1.1	Analytical Methods for estimation of Ezetimibe as bulk drug and in its pharmaceutical dosage form	91
7.1.1.1	Zero order, first order and second order derivative spectrophotometric methods.	91
7.1.1.2	Difference Spectrophotometric methods	98
7.1.1.3	Quantitative IR Spectroscopic methods	103
7.1.1.4	Stability Indicating Reverse Phase High Performance Liquid Chromatographic (HPLC) method	108
7.1.1.5	Reverse Phase High Performance Liquid Chromatographic (HPLC) method in human plasma	121
7.1.1.6	High Performance Thin Layer Chromatographic (HPTLC) method for estimation of formulation and degradation study	130
7.1.2	Analytical Methods for estimation of Pravastatin as bulk drug and in its pharmaceutical dosage form	140
7.1.2.1	Zero order spectrophotometry, first order and second order derivative Spectrophotometric methods.	140
7.1.2.2	Three wavelength & Difference Spectrophotometric methods	146
7.1.2.3	Quantitative IR Spectroscopic method	151
7.1.2.4	Stability Indicating Reverse Phase High Performance Liquid Chromatographic (HPLC) method	156
7.1.2.5	Bio Analytical Reverse Phase High Performance Liquid Chromatographic (HPLC) method for estimation in human plasma with UV detection.	165
7.1.2.6	High Performance Thin Layer Chromatographic (HPTLC) method for estimation of formulation and degradation study	172
7.1.3	Analytical Methods for estimation of Rosuvastatin as bulk drug and in its pharmaceutical dosage form	181

7.1.3.1	Zero order, first order derivative and three wavelength Spectrophotometric methods	181
7.1.3.2	Quantitative IR Spectroscopic method	188
7.1.3.3	Stability Indicating Reverse Phase High Performance Liquid Chromatographic (HPLC) method	192
7.1.3.4	Bio Analytical Reverse Phase High Performance Liquid Chromatography (HPLC) methods for estimation in human plasma	203
7.1.3.5	High Performance Thin Layer Chromatographic (HPTLC) method for formulation and degradation study	210
7.1.4	Analytical Methods for estimation of Simvastatin as bulk drug and in its pharmaceutical dosage form	219
7.1.4.1	Zero order, first and second order derivative Spectrophotometric methods	219
7.1.4.2	Three wavelength Spectrophotometric method	226
7.1.4.3	Quantitative IR Spectroscopic method	230
7.1.4.4	High Performance Thin Layer Chromatographic (HPTLC) method for formulation and degradation study	235
7.1.5	Analytical Methods for estimation of Lovastatin as bulk drug and its pharmaceutical dosage form	245
7.1.5.1	Zero order spectrophotometry, first order and second order derivative Spectrophotometric methods	245
7.1.5.2	Three wavelength Spectrophotometric methods	251
7.1.5.3	Quantitative IR Spectroscopic method	255
7.1.5.4	High Performance Thin Layer Chromatographic (HPTLC) method	259

7.2	BINARY MIXTURE	
7.2.1	Analytical Methods for simultaneous estimation of Ezetimibe and Simvastatin in its dosage form	269
7.2.1.1	First derivative zero crossing and absorbance ratio derivative zero crossing methods	270
7.2.1.2	Quantitative IR Spectroscopic method	279
7.2.1.3	Chemometric methods	
7.2.1.3.1	ILS and CLS	285
7.2.2	Analytical Methods for estimation of Ezetimibe and Pravastatin in combination dosage form	297
7.2.2.1	First derivative zero crossing and difference derivative zero crossing methods	298
7.2.2.2	Quantitative IR Spectroscopic method	304
7.2.2.3	Stability Indicating Reverse Phase High Performance Liquid Chromatographic (HPLC) method	309
7.2.2.4	High Performance Thin Layer Chromatographic (HPTLC) method	319
7.2.2.5	Chemometric methods	324
7.2.2.5.1	ILS and CLS	
7.2.3	Analytical Methods for estimation of Ezetimibe and Rosuvastatin in combination dosage form	338
7.2.3.1	First derivative zero crossing method	339
7.2.3.2	Quantitative IR Spectroscopic method	344
7.2.3.3	Stability Indicating Reverse Phase High Performance Liquid Chromatographic (HPLC) method	349
7.2.3.4	High Performance Thin Layer Chromatographic (HPTLC) method	362
7.2.3.5	Chemometric methods	
7.2.3.5.1	ILS and CLS	369
7.2.4	Analytical Methods for estimation of Ezetimibe and Lovastatin in combination dosage form	381
7.2.4.1	First derivative zero crossing and Ratio derivative zero	382

	crossing methods	
7.2.4.2	Quantitative IR Spectroscopic method	390
7.2.4.3	Chemometric Methods	
7.2.4.3.1	ILS and CLS	394
7.2.5	Development of High Performance Thin Layer Chromatographic (HPTLC) method for Simvastatin and Nicotinic acid	408
7.2.6	Development of High Performance Thin Layer Chromatographic (HPTLC) method for Ezetimibe and Simvastatin and Ezetimibe and Lovastatin	414
7.2.7	Stability Indicating Reverse Phase High Performance Liquid Chromatographic (HPLC) method for the estimation of Ezetimibe, Simvastatin and Lovastatin	420
7.2.8	Bio Analytical Reverse Phase High Performance Liquid Chromatographic (HPLC) method for estimation of Simvastatin and Lovastatin in presence of metabolites	439
CHAPTER 8	STATISTICAL ANALYSIS	450
CHAPTER 9	SUMMARY AND CONCLUSION	458
CHAPTER 10	RESEARCH PAPER: PUBLISHED AND COMMUNICATED	461
ABBREVIATION		